It plays a role in converting body fat into energy
a PDE-5 inhibitor attenuates the hydrolysis of cyclic guanosine monophosphate (cGMP, also called guanosine 3',5'-cyclic monophosphate), thereby increasing the persistence of cGMP, by inhibiting the activity of endogenous type V phosphodiesterase (PDE-5), it being understood that PDE-5 naturally regulates the degradation of cGMP to 5' guanosine monophosphate (5' GMP) in the corpus cavernosum
Emphasizing Personalization Every patients metabolic profile, sensitivity levels, and health goals are unique
In the efficacy-estimand analysis, participants taking the highest dose (12 mg) lost an average of 28.7% of their body weight at 68 weeks, about 71.2 pounds from a baseline of 248.5 pounds
Director & Superintendent Pharmacist MPharm, PIP GPhC Number: 2215377 Clinical Director MPharm Clinical Governance Lead MPharm, PgDip Deputy Superintendent Pharmacist Need something else